Global Pemetrexed Market Size By Type (100mg, 500mg), By Application (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Pemetrexed Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 3.7 billion by 2031, growing at a CAGR of 7.2% during the forecast period of 2023-2031. The market's expansion is driven by the increasing incidence of cancer worldwide, particularly non-small cell lung cancer (NSCLC) and mesothelioma, where pemetrexed is a widely used chemotherapy drug. Rising healthcare expenditure, improved access to oncology treatments, and growing awareness regarding advanced cancer therapies are further propelling market growth globally.

Drivers:

Increasing Cancer Prevalence:

The growing prevalence of cancer, particularly lung cancer and pleural mesothelioma, is a primary driver for the pemetrexed market. Factors such as smoking, pollution, and aging populations contribute to higher cancer incidence, fueling demand for effective chemotherapy agents like pemetrexed.

Rising Healthcare Expenditure and Access to Cancer Treatment:

Developing healthcare infrastructure, rising disposable incomes, and improved access to oncology drugs in emerging economies are enhancing market growth prospects.

Expansion of Combination Therapy Approaches:

Pemetrexed is increasingly being used in combination therapies with other drugs, improving survival rates and treatment outcomes, driving its market demand further.

Restraints:

Patent Expiry and Generic Competition:

The expiry of patents for branded pemetrexed products has led to increased competition from generics, which could impact market revenues for established pharmaceutical companies.

Side Effects Associated with Pemetrexed:

Like most chemotherapy drugs, pemetrexed can lead to severe side effects, including hematological and gastrointestinal issues, which may limit its adoption in certain patient populations.

Opportunity:

Emerging Markets and Untapped Regions:

Emerging economies, particularly in Asia-Pacific and Latin America, offer substantial growth opportunities due to rising cancer cases, increasing healthcare spending, and improving oncology treatment infrastructure.

Development of Personalized Medicine and Targeted Therapies:

The growing focus on personalized medicine and the integration of pemetrexed with targeted therapies open new avenues for market expansion.

Market by System Type Insights:

Based on the system type, the Injectable segment dominated the market in 2023 due to the widespread use of injectable pemetrexed in chemotherapy protocols for treating various types of cancer, particularly NSCLC and mesothelioma.

Market by End-use Insights:

The Hospital Pharmacies segment emerged as the largest end-use segment in 2023, accounting for the major share of the market. The prevalence of chemotherapy treatments administered in hospital settings contributes significantly to this segment’s dominance.

Market by Regional Insights:

Geographically, North America led the global pemetrexed market in 2023 due to a high prevalence of cancer, advanced healthcare infrastructure, and early adoption of innovative cancer therapies. However, the Asia-Pacific region is projected to witness the highest growth rate during the forecast period, driven by a rising cancer burden and improving healthcare facilities.

Competitive Scenario:

Leading companies operating in the Global Pemetrexed Market include Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Mylan N.V., Fresenius Kabi AG, Accord Healthcare Ltd., and Lupin Limited. These players are focusing on strategic collaborations, product launches, and expanding their generic pemetrexed portfolio to maintain market competitiveness.

Key Market Developments:

In 2023, Eli Lilly and Company expanded its oncology drug portfolio with new clinical studies evaluating combination therapies involving pemetrexed.

In 2022, Teva Pharmaceuticals launched its generic version of pemetrexed in multiple markets following patent expiry.

In 2024, Pfizer Inc. entered into a partnership to develop biosimilar versions of pemetrexed for emerging markets.

Scope of Work – Global Pemetrexed Market:

Report Metric Details

Market Size (2023) USD 2.1 Billion

Projected Market Size (2031) USD 3.7 Billion

CAGR (2023-2031) 7.2%

Market Segments By System Type (Injectable, Others), By End-use (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa)

Key Growth Drivers Rising Cancer Prevalence, Expansion of Combination Therapies, Increasing Healthcare Expenditure

Opportunities Emerging Markets Expansion, Integration with Targeted Therapies

FAQs:

1. What is the current market size of the Global Pemetrexed Market?

The Global Pemetrexed Market was valued at USD 2.1 billion in 2023.

2. What is the major growth driver of the Global Pemetrexed Market?

The major growth driver is the increasing prevalence of cancer, particularly non-small cell lung cancer and mesothelioma.

3. Which is the largest region during the forecast period in the Global Pemetrexed Market?

North America accounted for the largest market share in 2023, while Asia-Pacific is expected to register the highest growth during the forecast period.

4. Which segment accounted for the largest market share in the Global Pemetrexed Market?

The Injectable segment dominated the market in 2023 due to its widespread use in chemotherapy treatments.

5. Who are the key market players in the Global Pemetrexed Market?

Key players include Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Mylan N.V., Fresenius Kabi AG, Accord Healthcare Ltd., and Lupin Limited.

Would you like me to prepare this as a downloadable document (Word/PDF) for your use?